title: Weekly anthracycline in the treatment of advanced breast cancer.
abstract: In two consecutive prospective and randomized studies, very similar response rates (31 and 36% respectively) were obtained for weekly 20 mg doses of doxorubicin among 143 patients with advanced breast cancer. The treatment was well tolerated and most patients had only moderate, if any, complaints about this treatment.
authors.affiliation: Department for Medical Oncology and Radiotherapy, Norwegian Radium Hospital, Oslo.
authors.forename: S
authors.initials: S
authors.lastname: Gundersen
authors.forename: S
authors.initials: S
authors.lastname: Kvinnsland
authors.forename: O
authors.initials: O
authors.lastname: Klepp
authors.forename: E
authors.initials: E
authors.lastname: Lund
authors.forename: H
authors.initials: H
authors.lastname: Høst
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction
chemical_list: D004317:Doxorubicin